As manager of Pew's drug safety project, Cosel works on federal initiatives to ensure the safety and oversight of the U.S. pharmaceutical supply chain. Prior to joining Pew, Cosel worked on issues of pharmaceutical safety and appropriate prescribing for national advocacy Organization Community Catalyst, and in grassroots development and capacity-building with the Fund for Public Interest Research in Cambridge, Massachusetts.
Cosel received her M.Sc. in human rights from the London School of Economics and a BA from Yale University.
Recent WorkView All
Recent spikes in the price of certain off-patent medications have caused some legislators and health care professionals to advocate for using compounded drugs—drugs mixed by pharmacies—as a substitute for more expensive, FDA-approved medications. Though well-intentioned, this approach carries significant risks for patients and the sustainability of the drug approval system for the... Read More
As the debate over drug pricing persists on Capitol Hill, The Pew Charitable Trusts’ drug safety project is working to educate members of Congress about the dangers of allowing compounded drugs—drugs made by pharmacists—to serve as a low-cost alternative to FDA-approved medications. In advance of the U.S. House of Representatives’ Feb. 4 Oversight and Government Reform Committee hearing... Read More
In advance of the Jan. 28 hearing, “Generic Drug User Fee Amendments: Accelerating Patient Access to Generic Drugs,” Allan Coukell, senior director of health programs at The Pew Charitable Trusts, sent a letter to members of the U.S. Senate Committee on Health, Education, Labor, and Pensions. In the letter, Coukell highlights the risks of relying on compounded drugs—medicines made by... Read More